SANTA CLARA, Calif., May 22 /PRNewswire/ -- Applied Imaging Corp.
(Nasdaq: AICX) announced that the U.S. Patent and Trademark Office (PTO) has
issued a patent to the company for techniques used to analyze and combine
multiple DNA probe signals into a single result.
Fluorescence-labeled DNA probes are used in both clinical and research
settings to detect specific genetic abnormalities associated with the
development of cancer and other diseases. In many cases, a combination of
several DNA probes, each of which binds to a different DNA sequence in the
patient's chromosomes, may be needed for precise diagnosis. This patent
covers methods used to accurately image and interpret the results of multiple
DNA probes on a single specimen, providing more data to aid in the selection
of the most appropriate therapy.
Current oncology research is focused on the identification of specific
genetic abnormalities that identify which patients will respond to precisely
targeted molecular therapies. Data presented at the recent American Society
of Clinical Oncology Annual Meeting confirm that molecular targeting
strategies, utilizing fluorescent DNA probe results to select patients, have
been successful in treating patients with breast cancer and leukemia.
Promising new therapeutics, such as Herceptin(R) and Gleevec(R), are being
widely studied among patient populations selected using genetic test results.
Applied Imaging markets a range of clinical and research imaging systems
for fluorescence and brightfield microscopy applications, including the
Company's MDS(R), CytoVision(R), PowerGene(R) and Quips(R) product lines.
Patent Information
U.S Patent No. 6,225,636 entitled, "Multifluor-fluorescence in-situ
hybridization (M-FISH) imaging techniques using multiple multiband filters
with image registration" issued on May 1, 2001.
About Applied Imaging
Applied Imaging Corp., based in Santa Clara, California, is the leading
supplier of automated imaging systems utilized in genetics and pathology
laboratories for the analysis of chromosomes in cancer and prenatal disorders.
The Company has installed over 2000 imaging systems in 1000 laboratories in
more than 35 countries.
Herceptin(R) is a registered trademark of Genentech, Inc. Gleevec(R) is a
registered trademark of Novartis.
This press release contains forward looking statements as defined in the
Private Securities Litigation Reform Act of 1995, regarding, among other
matters, the Company's future financial performance as well as its research
and development and product development efforts. Forward looking statements
address matters that are subject to a number of risks and uncertainties,
including the uncertainty of clinical studies and regulatory approvals.
Actual results could differ materially from those projected in the
forward-looking statement as a result of a number of factors including the
failure of the Company to successfully develop and commercialize its
micrometastasis or genetic instrument business, and other such factors as set
forth in the Company's form 10-K for the year ended December 31, 2000 as filed
with the Securities and Exchange Commission.
For additional information on Applied Imaging via fax, please dial
1-800-PRO-INFO, (732-544-2850 outside of the U.S.), code AICX, or visit the
Company's web site at http://www.aicorp.com .
SOURCE Applied Imaging Corp.
 back to top
Related links:
http://www.aicorp.com
CONTACT:
Barry Hotchkies, CFO of Applied Imaging
Corp., 408-562-0250; or General, Pam Roberts, Investors, James
Hoyne, both of The Financial Relations Board, 415-986-1591
|
